- $36.71bn
- $43.10bn
- $9.89bn
Biogen to acquire RayThera for $1 billion
Brief: Biogen Expands Immunology Pipeline With Agreement To Acquire Raythera Inc.
Brief: Biogen Canada Disappointed By Outcome Of Pan-Canadian Pharmaceutical Alliance Negotiations For Skyclarys
Factbox: Global drugmakers invest billions to boost US presence
Biogen to pay $18.9 million to settle investors' claims over Alzheimer's drug
U.S. STOCKS ON THE MOVE -Honeywell, Broadcom, Carlyle
U.S. STOCKS ON THE MOVE-UnitedHealth, Pinterest, Celcuity
Biogen up after FDA grants 'breakthrough' tag for neuromuscular disorder drug
Brief: UCB And Biogen Announce Positive DZP Phase 3 Study Results
Italy probes Biogen for allegedly hindering sales of rival's MS drug (updated)
Italy's antitrust regulator opens probe into US Biogen over alleged dominant position
Denali falls after scrapping development of Parkinson's drug
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study (updated)
Biogen, Denali scrap Parkinson's drug after failure in mid-to-late stage study
Street View: Skeptical on experimental Alzheimer's drug, awaits full data
U.S. RESEARCH ROUNDUP- Applied Materials, NVIDIA, Thermo Fisher Scientific
U.S. STOCKS ON THE MOVE-Advanced Energy, Bel Fuse, Cerebras
U.S. STOCKS ON THE MOVE-Klarna, Biogen, Legence
Biogen climbs on plans to advance development of experimental Alzheimer's therapy